問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Shin Kong Memorial Wu Ho-Su Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 111Taipei CityShih Lin

Recruiting Trial

52Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

142Cases

2021-01-04 - 2025-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2009-12-01 - 2014-01-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2024-02-27 - 2030-01-27

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting1Sites

Suspended15Sites

2025-09-30 - 2032-03-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2026-01-01 - 2031-09-18

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

2023-06-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
19Sites

Recruiting19Sites

2021-08-15 - 2026-05-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-09-01 - 2028-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2023-07-27 - 2027-07-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2025-01-01 - 2030-12-31

Phase III

Active
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patients with generalized Myasthenia Gravis, followed by an open-label extension phase

  • Condition/Disease

    Generalized Myasthenia Gravis

  • Test Drug

    Remibrutinib

Participate Sites
5Sites

Recruiting5Sites

1 3 4 5 6 7 15
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB